-transparent.png){kind=logo}
Bromocriptine therapy may cause regression of prolactinomas, but its effect on nonsecretory pituitary tumors is uncertain. Conventional treatment for such "functionless" tumors is surgery and/or radiotherapy, but recurrences pose a therapeutic dilemma. We describe a patient with such a tumor treated by surgery and radiotherapy who presented with recurrent disease 14 days later. On treatment with bromocriptine, 20 mg daily for 25 months, the intrasellar tumor recurrence had diminished in size and a suprasellar extension had almost disappeared. Bromocriptine therapy may therefore benefit some patients with nonsecretory pituitary tumors considered unsuitable for surgery or radiotherapy.
D G Johnston, and
K Hall, and
A McGregor, and
W M Ross, and
P Kendall-Taylor, and
R Hall
January 2014,
Handbook of clinical neurology,
D G Johnston, and
K Hall, and
A McGregor, and
W M Ross, and
P Kendall-Taylor, and
R Hall
January 1984,
No shinkei geka. Neurological surgery,
D G Johnston, and
K Hall, and
A McGregor, and
W M Ross, and
P Kendall-Taylor, and
R Hall
March 2008,
Endocrinology and metabolism clinics of North America,
D G Johnston, and
K Hall, and
A McGregor, and
W M Ross, and
P Kendall-Taylor, and
R Hall
October 2022,
Brain tumor pathology,
D G Johnston, and
K Hall, and
A McGregor, and
W M Ross, and
P Kendall-Taylor, and
R Hall
April 2018,
Pituitary,
D G Johnston, and
K Hall, and
A McGregor, and
W M Ross, and
P Kendall-Taylor, and
R Hall
January 1962,
Journal of neurosurgery,
D G Johnston, and
K Hall, and
A McGregor, and
W M Ross, and
P Kendall-Taylor, and
R Hall
January 1996,
Annual review of medicine,
D G Johnston, and
K Hall, and
A McGregor, and
W M Ross, and
P Kendall-Taylor, and
R Hall
September 1982,
JAMA,
D G Johnston, and
K Hall, and
A McGregor, and
W M Ross, and
P Kendall-Taylor, and
R Hall
May 1989,
Clinical endocrinology,
D G Johnston, and
K Hall, and
A McGregor, and
W M Ross, and
P Kendall-Taylor, and
R Hall
July 1996,
Neurosurgical focus,
